Brokerages expect C R Bard Inc (NYSE:BCR) to report earnings of $3.12 per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for C R Bard’s earnings, with the lowest EPS estimate coming in at $3.08 and the highest estimate coming in at $3.18. C R Bard reported earnings per share of $2.77 during the same quarter last year, which indicates a positive year-over-year growth rate of 12.6%. The company is scheduled to announce its next earnings report on Thursday, January 25th.

On average, analysts expect that C R Bard will report full year earnings of $11.86 per share for the current year, with EPS estimates ranging from $11.78 to $11.96. For the next fiscal year, analysts anticipate that the firm will post earnings of $12.94 per share, with EPS estimates ranging from $12.49 to $13.32. Zacks’ EPS averages are an average based on a survey of analysts that cover C R Bard.

C R Bard (NYSE:BCR) last released its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. C R Bard had a net margin of 14.75% and a return on equity of 48.28%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 EPS.

Several analysts have recently weighed in on BCR shares. Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $360.00 price objective on the stock in a report on Monday, July 31st. BidaskClub lowered C R Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Jefferies Group LLC reaffirmed a “hold” rating on shares of C R Bard in a research note on Thursday, August 3rd. BMO Capital Markets reaffirmed a “hold” rating and issued a $317.00 price target on shares of C R Bard in a research note on Tuesday, July 11th. Finally, Cowen and Company reaffirmed a “hold” rating and issued a $317.00 price target on shares of C R Bard in a research note on Friday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $292.00.

In related news, insider Timothy P. Collins sold 55,818 shares of the company’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $322.03, for a total value of $17,975,070.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David M. Barrett sold 3,344 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $327.31, for a total value of $1,094,524.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 136,568 shares of company stock valued at $43,932,079. 0.80% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of BCR. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in C R Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 190 shares during the period. Parallel Advisors LLC grew its stake in C R Bard by 2.8% in the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after acquiring an additional 14 shares during the period. Captrust Financial Advisors acquired a new position in C R Bard in the second quarter valued at about $192,000. Choate Investment Advisors acquired a new position in C R Bard in the second quarter valued at about $201,000. Finally, Stock Yards Bank & Trust Co. acquired a new position in C R Bard in the second quarter valued at about $207,000. 79.27% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/04/c-r-bard-inc-bcr-expected-to-announce-earnings-of-3-12-per-share.html.

Shares of C R Bard (BCR) opened at $333.86 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. The stock has a market cap of $24.34 billion, a price-to-earnings ratio of 28.98, a P/E/G ratio of 2.57 and a beta of 0.53. C R Bard has a twelve month low of $203.63 and a twelve month high of $335.84.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. C R Bard’s payout ratio is currently 13.70%.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Get a free copy of the Zacks research report on C R Bard (BCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with MarketBeat.com's FREE daily email newsletter.